RELIEF THERAPEUTICS Holding AG (OTCQB: RLFTF) plunged down -39.84 to 0.379 at yesterday’s close. The Company Volume was 104.26M in contrast with its Average Weekly volume of 31.20M.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
What they do?
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Relief Therapeutics Holding AG is a Swiss drug development company specializing in clinical stage drugs, primarily developing products of natural human origin. This company is focused on developing pharmaceutical products for diabetic complications and respiratory diseases, including Aviptadil and Atexakin alfa.
Read More
Latest Development
Thomaz Burckhardt, the member of the RELIEF THERAPEUTICS Holding AG’s Board of Directors, has resigned effective immediately. Burckhardt has resigned to devote his time and effort to other duties and interests.
The Board of Directors and I would like to thank Thomaz for his many contributions to the Company throughout the years. We wish him well in his future endeavors, said Raghuram Selvaraju, Chairman of the Board of Relief.
Relief will evaluate candidates for the position of an independent director who has extensive experience in the life sciences/healthcare with respect to filling the current vacancy.
Relief will continually assess its options for growing its Board and Executive Management team. This will enable Relief to maximize its ability to execute its business strategy in the future.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Conclusion
Biotechnology is entering an era that some experts consider to be the golden age. A new era of medical science is enabling new ways to treat and prevent diseases previously unimaginable. Stocks in biotech offer investors the chance to make a killing during this period.
